Medical Innovation
Americans today are benefiting from medical developments and discoveries that took shape almost two decades ago. On average, the travel time of an experimental drug from the lab to patients is 12 to15 years. Lawmakers need to realize the considerable impact that federal policies can have on maintaining the future of drug discovery and innovation.
All Americans, especially the aging, want the best therapies for life-threatening diseases and disabling and chronic conditions. A core goal of the Alliance for Aging Research is to encourage policies which will lead to newer and better treatments to improve the health and independence of Americans as they age.
Related Publications
-
DocumentBone Health of Americans is in Jeopardy
In an Alliance for Aging Research, National Osteoporosis Foundation (NOF) joint briefing, Dr. Joan Lappe presented on the human burden of osteoporosis and the need for continued research into prevention and treatment options. Her slides are available here. -
DocumentThe Value of Innovation in Osteoporosis
In an Alliance for Aging Research, National Osteoporosis Foundation (NOF) joint briefing, Rachael Fleurence, PhD, presented on the current economic burden of osteoporosis and the value of innovation in reducing that burden. Her slides are available here. -
Brochure, ReportThe Silver Book: Chronic Disease and Medical Innovation--Osteoporosis
The first volume of The Silver Book was launched in 2006 and has quickly become a trusted resource for health policy practitioners. The Silver Book®: Osteoporosis is the latest volume in this important collection. Each section in the volume includes charts, statistics, and key findings that together paint a comprehensive picture of the burden of osteoporosis and the tremendous potential of innovation. Much of the data focuses on the older population—those most at risk for osteoporosis-related fractures.
